PYC THERAPEUTICS LIMITED

*Disclaimer

PYC THERAPEUTICS LIMITED (ASX: PYC)

🔗 📄 📈

PYC: Successful Toxicology Results Pave Way for Phase 2 Trial

PYC THERAPEUTICS LIMITED

PYC is advancing three RNA drugs into human studies before the end of 2024.
The company's lead asset is progressing into a Phase 2 clinical trial for Retinitis Pigmentosa type 11 (RP11).
Successful toxicology studies and genotoxicity studies have paved the way for the Phase 2 trial.

2023-07-18 08:43:00

PYC: FIRST PATIENT DOSED IN EYE DISEASE CLINICAL TRIAL

PYC THERAPEUTICS LIMITED

PYC has dosed the first patient with VP-001, an investigational drug designed to halt the progression of Retinitis Pigmentosa Type 11 (RP11), a blinding eye disease with no current treatment options.
The first dosed patient will be followed by two more in the low dose group, after which safety data will be reviewed by the Safety Review Committee to decide if the next, mid-dose group can proceed.
VP-001 is the first potential treatment for RP11, a disease caused by insufficient expression of the PRPF31 gene, affecting approximately 1 in 100,000 people and leading to legal blindness in midlife.

2023-06-30 08:17:00

PYC: Successful Completion of $30m Placement

PYC THERAPEUTICS LIMITED

PYC has raised $30 million in a placement to sophisticated and institutional investors, extending the Company's cash runway to around $52 million.
The funding enables the Company to progress drug candidates for rare blinding eye diseases and a neurodevelopmental disorder, as well as evaluate business development opportunities.
The Placement was conducted at a price of $0.055 per share and was supported by both existing major shareholders and new institutional investors.

2023-05-11 10:05:00

PYC: Commencement of First Clinical Study in RP11

PYC THERAPEUTICS LIMITED

PYC has received approval to commence the first clinical study for the treatment of Retinitis Pigmentosa type 11 (RP11).
The Phase 1 Platypus study will evaluate the safety and tolerability of a single dose of the investigational drug VP-001.
RP11 is a progressive and irreversible blinding eye disease with no current treatment options, representing an estimated >$1 billion p.a. addressable market.

2023-04-26 08:58:00

PYC: Second Drug Program Progressing to Human Trials

PYC THERAPEUTICS LIMITED

PYC Therapeutics is progressing its second drug development program, PYC-001, for Autosomal Dominant Optic Atrophy (ADOA) to human trials after successful non-clinical data.
ADOA is a progressive and blinding eye disease of childhood with no current treatment options, representing an estimated $2 billion market.
PYC's investigational drug candidate is expected to enter human trials in 2024 after completion of formal toxicological studies.

2023-04-03 09:54:00

PYC: FDA Clears PYC to Commence First Human Trials in RP11

PYC THERAPEUTICS LIMITED

PYC Therapeutics has advanced their drug candidate, VP-001, into human trials for the treatment of Retinitis Pigmentosa type 11 (RP11) with FDA approval.
Patients with RP11 will be dosed with VP-001 in 2Q 2023 after obtaining human ethics approval.
This milestone represents a potential treatment option for RP11 patients and validation of PYC's platform technology for their entire pipeline.

2023-03-06 09:21:00

PYC: VP-001 IND Lodgement

PYC THERAPEUTICS LIMITED

PYC Therapeutics has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration in support of its lead drug candidate, VP-001.
If accepted, VP-001 will be the first investigational drug candidate with the potential to modify the course of Retinitis Pigmentosa type 11.
PYC Therapeutics is a biotechnology company creating a new generation of RNA therapies through combining their drug design capabilities with a proprietary drug delivery platform.

2023-02-02 09:06:00

PYC: Quarterly Activities/Appendix 4C Cash Flow Report

PYC THERAPEUTICS LIMITED

PYC Therapeutics is a biotechnology company creating a new generation of RNA therapeutics to change the lives of patients with genetic diseases.
The Company is progressing multiple first-in-class drug candidates with the potential to address the underlying cause of genetic diseases into clinical trials.
PYC's most advanced program, a treatment for a progressive blinding eye disease, is set to enter clinical (human) studies in the current quarter.

2023-01-20 08:21:00

ASX Briefs...everything...in 3 bullet points

ASX Briefs

*Disclaimer

PYC THERAPEUTICS LIMITED (ASX: PYC)

PYC: Successful Toxicology Results Pave Way for Phase 2 Trial

PYC THERAPEUTICS LIMITED

PYC: FIRST PATIENT DOSED IN EYE DISEASE CLINICAL TRIAL

PYC THERAPEUTICS LIMITED

PYC: Successful Completion of $30m Placement

PYC THERAPEUTICS LIMITED

PYC: Commencement of First Clinical Study in RP11

PYC THERAPEUTICS LIMITED

PYC: Second Drug Program Progressing to Human Trials

PYC THERAPEUTICS LIMITED

PYC: FDA Clears PYC to Commence First Human Trials in RP11

PYC THERAPEUTICS LIMITED

PYC: VP-001 IND Lodgement

PYC THERAPEUTICS LIMITED

PYC: Quarterly Activities/Appendix 4C Cash Flow Report

PYC THERAPEUTICS LIMITED